PRAISE-U consortium meets in Rotterdam: First lessons from pilots and next steps
Pilots in focus
Day one, chaired by Professor Hendrik Van Poppel, focused on outcomes from pilot sites in Galicia, Poland, Althaia (Manresa), Lithuania, and Ireland. Professor Monique Roobol opened with a recap of the consortium’s progress, followed by Meike van Harten on preliminary clinical results from all pilot sites.
Then came the experience from the leads of all pilot teams, where several topics and themes were discussed. Pilots had been asked to consider what had gone well, but also to consider key challenges and barriers in their settings.
Key barriers
A strong barrier theme was communication, with screening participants themselves, but also with local and national decision makers and screening agencies. Better strategies are needed to explain overdiagnosis, manage expectations, and reassure those not invited. Collaborative user boards (CUB) were discussed as an interesting format for gathering insights from each pilot setting. These CUBs are essentially focus groups involving multi stakeholders (screening participants, healthcare professionals, screening agencies, decision makers and healthcare providers, for example).
The day ended with cross-border reflections from Sweden, Czech Republic, and Estonia, highlighting lessons learned from their pilots. Swedish regions are working together on organised prostate cancer testing, and some regions will enter their fourth year of implementation. Czechia is running a national programme using the regular GP check-ups as the basis for the first PSA tests - they are using this to evaluate uptake and also alignment to the screening process, and will continue to learn from the data how to do things better.
Linking pilots and evaluation
Day two turned to dialogue between pilots and the evaluation teams. Arunah Chandran (IARC) chaired these interactive and engaging sessions exploring how evaluators can support pilots and what pilots need in return. The exchange on psycho-social aspects, cost effectiveness, the clinical algorithm and health system scalability and sustainability set the stage for the future evaluation process. This exchange reinforced that evaluation frameworks must stay grounded in real-world practice.
Jarka Bloemberg and Sorcha Lanigan updated the group on communications, underlining the importance of telling a coherent PRAISE-U story to both policymakers and the public.
Looking beyond the project, Sarah Collen chaired a session on sustainability. Monique Roobol shared synergies with EUCanScreen, while Susan Evans Axelsson and Roobol presented PRAISE-U+ and the EAU UroEvidenceHub, opening opportunities for long-term data sharing.
Moving forward
The Rotterdam meeting underscored both the progress and complexity of implementing prostate cancer screening. Evidence of cost-effectiveness will be crucial, as will stronger communication strategies that bridge population-level goals and individual expectations.
With the end of the project coming up early 2026, it was clear that all stakeholders are very committed to collect the data needed to convince politicians to stop opportunistic screening and start using the PRAISE-U algorithm. Most of all, the event highlighted the value of collective learning across borders. PRAISE-U is not only a research initiative—it is a European effort to design credible, sustainable, and prostate cancer screening.